William P Katt (William Katt)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 15

Top Venues

bioRxiv : the preprint server for biology

Communications biology

Research square

OncoTargets and therapy

Cornell University

Yale University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Cornell University Jun 10 2009

United States

Research Associate :: Molecular Medicine

Education History

Yale University Sep 01 2004 - Jun 01 2009

United States

PHD :: Chemistry

Yale University Sep 01 2004 - Jun 01 2006

United States

MSC :: Chemistry

Rensselaer Polytechnic Institute Sep 01 2003 - May 19 2004

United States

MSC :: Chemistry

Rensselaer Polytechnic Institute Sep 01 2000 - Jun 11 2003

United States

BSC :: Chemistry & Computer Science

Publications

Cody Aplin, Kara A Zielinski, Suzette Pabit, Deborah Ogunribido, William P Katt, Lois Pollack, Richard A Cerione, Shawn K Milano
Distinct conformational states enable transglutaminase 2 to promote cancer cell survival versus cell death. Communications biology 7 (1) (2024)
Cody Aplin, Kara A Zielinski, Suzette A Pabit, Deborah Ogunribido, William P Katt, Lois Pollack, Richard A Cerione, Shawn K Milano
Defining the conformational states that enable transglutaminase 2 to promote cancer cell survival versus cell death. bioRxiv : the preprint server for biology (2024)
Cody Aplin, Kara A Zielinski, Suzette Pabit, Deborah Ogunribido, William P Katt, Lois Pollack, Richard A Cerione, Shawn K Milano
Distinct conformational states enable transglutaminase 2 to promote cancer cell survival versus cell death. Communications biology 7 (1) (2024)
Cody Aplin, Kara A Zielinski, Suzette A Pabit, Deborah Ogunribido, William P Katt, Lois Pollack, Richard A Cerione, Shawn K Milano
Defining the conformational states that enable transglutaminase 2 to promote cancer cell survival versus cell death. bioRxiv : the preprint server for biology (2024)
Cody Aplin, Kara A Zielinski, Suzette Pabit, Deborah Ogunribido, William P Katt, Lois Pollack, Richard A Cerione, Shawn K Milano
Distinct conformational states enable transglutaminase 2 to promote cancer cell survival versus cell death. Communications biology 7 (1) (2024)
Cody Aplin, Kara A Zielinski, Suzette Pabit, Deborah Ogunribido, William P Katt, Lois Pollack, Richard A Cerione, Shawn K Milano
Distinct conformational states enable transglutaminase 2 to promote cancer cell survival versus cell death. Communications biology 7 (1) (2024)
Santiago Peralta, William P Katt, Cheryl Balkman, Scott Butler, Patrick Carney, Amy Todd-Donato, Matthew Drozd, Gerald Duhamel, Nadine Fiani, Jordan Ford, Jennifer Grenier, Jessica Hayward, Kristiina Heikinheimo, Kelly Hume, Elizabeth S Moore, Rishi Puri, Skylar Sylvester, Sydney Warshaw, Suzin Webb, Andrew C White, Alexandra Wright, Richard A Cerione
Opportunities for targeted therapies: trametinib as a therapeutic approach to canine oral squamous cell carcinomas. Research square (2024)
Cody Aplin, Kara A Zielinski, Suzette Pabit, Deborah Ogunribido, William P Katt, Lois Pollack, Richard A Cerione, Shawn K Milano
Distinct conformational states enable transglutaminase 2 to promote cancer cell survival versus cell death. Communications biology 7 (1) (2024)
Cody Aplin, Kara A Zielinski, Suzette A Pabit, Deborah Ogunribido, William P Katt, Lois Pollack, Richard A Cerione, Shawn K Milano
Defining the conformational states that enable transglutaminase 2 to promote cancer cell survival versus cell death. bioRxiv : the preprint server for biology (2024)
Cody Aplin, Kara A Zielinski, Suzette A Pabit, Deborah Ogunribido, William P Katt, Lois Pollack, Richard A Cerione, Shawn K Milano
Defining the conformational states that enable transglutaminase 2 to promote cancer cell survival versus cell death. bioRxiv : the preprint server for biology (2024)
Santiago Peralta, William P Katt, Cheryl Balkman, Scott Butler, Patrick Carney, Amy Todd-Donato, Matthew Drozd, Gerald Duhamel, Nadine Fiani, Jordan Ford, Jennifer Grenier, Jessica Hayward, Kristiina Heikinheimo, Kelly Hume, Elizabeth S Moore, Rishi Puri, Skylar Sylvester, Sydney Warshaw, Suzin Webb, Andrew C White, Alexandra Wright, Richard A Cerione
Opportunities for targeted therapies: trametinib as a therapeutic approach to canine oral squamous cell carcinomas. Research square (2024)
Thuy-Tien T Nguyen, William P Katt, Richard A Cerione
Alone and together: current approaches to targeting glutaminase enzymes as part of anti-cancer therapies. Future drug discovery 4 (4) (2023)
Kai Su Greene, Annette Choi, Matthew Chen, Nianhui Yang, Ruizhi Li, Yijian Qiu, Michael J Lukey, Katherine S Rojas, Jonathan Shen, Kristin F Wilson, William P Katt, Gary R Whittaker, Richard A Cerione
Inhibiting Glutamine Metabolism Blocks Coronavirus Replication in Mammalian Cells. bioRxiv : the preprint server for biology (2023)
William P Katt, Cody Aplin, Richard A Cerione
Exploring the Role of Transglutaminase in Patients with Glioblastoma: Current Perspectives. OncoTargets and therapy 15 (2022)
William P Katt
Patents targeting the Warburg effect for cancer therapy: an interview with William P Katt. Pharmaceutical patent analyst 9 (1) (2020)

William P Katt.css-eqlu8i{font-size:small;padding-left:4px;} (William Katt)

Publication Activity (10 Years)

Top Topics

Top Venues

William P Katt (William Katt)